港股创新药板块早盘活跃，恒生创新药ETF（159316）盘中获3500万份净申购

Core Viewpoint - The Hong Kong innovative drug sector is experiencing active performance, with significant increases in various stocks and a notable inflow into the Hang Seng Innovative Drug ETF [1] Group 1: Market Performance - As of 10:40, the Hang Seng Innovative Drug Index rose by 0.6%, with notable stock increases: Lepu Biotech-B up 5.1%, Innovent Biologics up 3.3%, Ascentage Pharma-B up 2.8%, and CStone Pharmaceuticals up 2.7% [1] - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume exceeding 250 million yuan, with a net subscription of 35 million units [1] Group 2: Future Outlook - Looking ahead to the second half of 2025, major academic conferences such as the World Conference on Lung Cancer (WCLC), European Society for Medical Oncology (ESMO), American College of Rheumatology (ACR), and American Association for the Study of Liver Diseases (AASLD) are expected to continuously catalyze the innovative drug sector [1] Group 3: Index Revision - The Hang Seng Innovative Drug Index has announced a revision to its compilation scheme, explicitly excluding CXO companies, with the new rules set to take effect on August 11 [1] - This index will become one of the first "pure" innovative drug indices with 100% purity among ETF-tracked indices, enhancing its appeal to investors [1]